Endocrine Pathology

, Volume 13, Issue 4, pp 331–339 | Cite as

An immunohistochemical survey of nine cases of medullary carcinoma of thyroid including reactivity for Cox-1 and Cox-2 enzymes

  • C. David Bell
  • Sergio Vidal
  • Kalman Kovacs
  • Eva Horvath
  • Fabio Rotondo
Clinical Research


There has been much recent investigation of the cyclooxygenase (Cox) enzymes in tumor biology, but, to our knowledge, no study has yet been published describing Cox activity in medullary carcinoma of the thyroid (MTC). Nine cases of MTC from the past 10 yr were retrieved from our hospital archives. Slides cut from formalin-fixed paraffin-embedded tumor tissue from these cases were assessed for the activities of Cox-1 and Cox-2 enzymes by immunohistochemistry as well as by a battery of immunohistochemical stains for intermediate filaments, peptide hormone, and proliferation and promoter antigens. The staining reactions were semiquantitatively assessed and scored for comparison with each other as well as with each patient’s clinical presentation and course. Staining for Cox-1 and Cox-2 enzymes was present only in tumorous tissue, not in nontumorous thyroid tissue or C-cells. Cox-2 staining was not consistently increased over Cox-1 staining; however, Cox-2 staining bore statistically significant correlations with the expression of low molecular weight keratin, thyroid-transforming factor-1, topoisomerase, and MIB1. Hyperplastic C-cells from patients with diverse physiologic conditions and from three patients with C-cell hyperplasia accompanying medullary carcinoma or multiple endocrine neoplasia type IIa showed no reactivity for the Cox antibodies. It appears that Cox enzyme immunoreactivity is present only in the neoplastic C-cells of medullary carcinoma, but with variable expression. A practical application of the preceding finding might involve the use of Cox staining to distinguish invasive medullary carcinoma cells from hyperplastic C-cells.

Key Words

C-cells medullary carcinoma of the thyroid cyclooxygenase immunohistochemistry 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Dimberg J, Samuelsson A, Hugander A, Soderkvist P. Differential expression of cyclooxygenase 2 in human colorectal cancer. Gut 45:730–732, 1999.PubMedCrossRefGoogle Scholar
  2. 2.
    Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183–1188, 1994.PubMedGoogle Scholar
  3. 3.
    Koga H, Shotaro S, Ohishi M, et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 29:688–696, 1999.PubMedCrossRefGoogle Scholar
  4. 4.
    Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 59:4356–4362, 1999.PubMedGoogle Scholar
  5. 5.
    Morris CD, Armstrong GR, Bigley G, Green H, Attwood SEA. Cyclooxygenase-2 expression in the Barrett’s metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 96:990–996, 2001.PubMedGoogle Scholar
  6. 6.
    Okami J, Yamamoto H, Fujiwara Y, et al. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res 5:2018–2024, 1999.PubMedGoogle Scholar
  7. 7.
    Saukkonen K, Nieminen O, van Rees B, et al. Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. Clin Cancer Res 7:1923–1931, 2001.PubMedGoogle Scholar
  8. 8.
    Sheehan KM, Sheahan K, O’Donoghue DP, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 282:1254–1257, 1999.PubMedCrossRefGoogle Scholar
  9. 9.
    Fujita T, Matsui M, Takaku K, et al. Size and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 58:4823–4826, 1998.PubMedGoogle Scholar
  10. 10.
    Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94:3336–3340, 1997.PubMedCrossRefGoogle Scholar
  11. 11.
    Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is upregulated in human pancreatic cancer. Cancer Res 59:987–990, 1999.PubMedGoogle Scholar
  12. 12.
    Uefuji K, Ichikura T, Mochizuki H, Shinomiya N. Expression of cyclooxygenase-2 protein in gastric adenocarcinoma. J Surg Oncol 69:168–172, 1998.PubMedCrossRefGoogle Scholar
  13. 13.
    Zimmermann KC, Sarbia M, Weber A, et al. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 59:198–204, 1999.PubMedGoogle Scholar
  14. 14.
    Stack E, DuBois RN. Role of cyclooxygenase inhibitors for the prevention of colorectal cancer. Gastroenterol Clin North Am 30:1001–1010, 2001.PubMedCrossRefGoogle Scholar
  15. 15.
    Krishnan K, Brenner DE. Prostaglandin inhibitors and the chemoprevention of noncolonic malignancy. Gastroenterol Clin North Am 30:981–1000, 2001.PubMedCrossRefGoogle Scholar
  16. 16.
    Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42:73–78, 2000.PubMedCrossRefGoogle Scholar
  17. 17.
    Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. JNCI 90:455–460, 1998.PubMedCrossRefGoogle Scholar
  18. 18.
    Jaekel EC, Raja S, Tan J, et al. Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor d with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 127:1253–1259, 2001.Google Scholar
  19. 19.
    Lee LM, Pan CC, Cheng Cj, Chi CW, Liu TY. Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. Anticancer Res 21:1291–1294, 2001.PubMedGoogle Scholar
  20. 20.
    Ranelletti FO, Almadori G, Rocca B, et al. Prognostic significance of cyclooxygenase-2 in laryngeal squamous cell carcinoma. Int J Cancer 95:343–349, 2001.PubMedCrossRefGoogle Scholar
  21. 21.
    Ristimaki A, Nieminen O, Saukkonen K, et al. Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol 158:849–853, 2001.PubMedGoogle Scholar
  22. 22.
    Shappell SB, Manning S, Boeglin WE, et al. Alterations in lipooxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia 3:287–303, 2001.PubMedCrossRefGoogle Scholar
  23. 23.
    Subbarayan V, Sabichi AL, Llansa N, Lippman SM, Menter DG. Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells. Cancer Res 61:2720–2726, 2001.PubMedGoogle Scholar
  24. 24.
    Ikawa H, Kameda H, Kamitani H, et al. Effect of PPAR activators on cytokine-stimulated cyclooxygenase-2 expression in human colorectal carcinoma cells. Exp Cell Res 267:73–80, 2001.PubMedCrossRefGoogle Scholar
  25. 25.
    Fosslien E. Review: molecular pathology of cyclooxygenase-2 in cancer induced angiogenesis. Ann Clin Lab Sci 31:325–348, 2001.PubMedGoogle Scholar
  26. 26.
    Liu X, Yao S, Kirschenbaum A, Levine AC. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down regulates bcl-2 expression in LNCaP cells. Cancer Res 58:4245–4249, 1998.PubMedGoogle Scholar
  27. 27.
    Hull MA, Fenwick SW, Chapple KS, et al. Cyclooxygenase-2 expression in colorectal cancer liver metastases. Clin Exp Metastasis 18:21–27, 2000.PubMedCrossRefGoogle Scholar
  28. 28.
    Wolff H, Saukkonen K, Anttila S, et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 58:4997–5001, 1998.PubMedGoogle Scholar
  29. 29.
    Salmenkivi K, Haglund C, Ristimaki A, et al. Increased expression of cyclooxygenase-2 in malignant pheochromocytomas. J Clin Endocrinol Metab 86:5615–5619, 2001.PubMedCrossRefGoogle Scholar
  30. 30.
    Berg J, Stocher M, Bogner S, et al. Inducible cyclooxygenase-2 gene expression in the human thyroid epithelial cell line Nthy-ori3-1. Inflamm Res 49:139–143, 2000.PubMedCrossRefGoogle Scholar
  31. 31.
    Frenkian M, Segond N, Pidoux E, Cohen R, Jullienne A. Indomethacin, a cox inhibitor, enhances 15-PGDH and decreases human tumoral C cells proliferation. Prostaglandins Other Lipid Mediat 65:11–20, 2001.PubMedCrossRefGoogle Scholar
  32. 32.
    Specht MC, Tucker ON, Hocever M, et al. Cyclooxygenase-2 expression in thyroid nodules. J Clin Endocrinol Metab 87:358–363, 2002.PubMedCrossRefGoogle Scholar
  33. 33.
    Papotti M, Sambataro D, Pecchioni C, Bussolati G. The pathology of medullary carcinoma of the thyroid: review of the literature and personal experience on 62 cases. Endocr Pathol 7:1–20, 1996.PubMedGoogle Scholar
  34. 34.
    Papotti M, Kumar U, Volante M, et al. Immunohistochemical detection of somatostatin receptor types 1–5 in medullary carcinoma of the thyroid. Clin Endocrinol 54:641–649, 2001.CrossRefGoogle Scholar
  35. 35.
    Neonakis E, Thomas GA, Davies HG, Wheeler MH, Williams ED. Expression of calcitonin and somatostatin peptide and mRNA in medullary thyroid carcinoma. World J Surg 18:588–593, 1994.PubMedCrossRefGoogle Scholar
  36. 36.
    Krueger JE, Maitra A, Albores-Saavedra J. Inherited medullary microcarcinoma of the thyroid: a study of 11 cases. Am J Surg Pathol 24:853–858, 2000.PubMedCrossRefGoogle Scholar
  37. 37.
    Lloyd RV, Sisson JC, Marangos PJ. Calcitonin, carcinoembryonic antigen, and neuron-specific enolase in medullary thyroid carcinoma. Cancer 51:2234–2239, 1983.PubMedCrossRefGoogle Scholar
  38. 38.
    Lam KY, Lui MC, Lo CY. Cytokeratin expression profiles in thyroid carcinomas. Eur J Surg Oncol 27:631–635, 2001.PubMedCrossRefGoogle Scholar
  39. 39.
    Depondt J, Shabana AH, Sawaf H, Gehanno P, Forest N. Cytokeratin alterations as diagnostic and prognostic markers of oral and pharyngeal carcinomas: a prospective study. Eur J Oral Sci 107:442–454, 1999.PubMedCrossRefGoogle Scholar
  40. 40.
    Hansson A, Bloor BK, Haig Y, et al. Expression of keratins in normal, immortalized and malignant oral epithelia in organotypic culture. Oral Oncol 37:419–430, 2001.PubMedCrossRefGoogle Scholar
  41. 41.
    Ansink A, Mooi WJ, Doornewaard G, et al. Cytokeratin subtypes and involucrin in squamous cell carcinoma of the vulva. Cancer 76:638–643, 1995.PubMedCrossRefGoogle Scholar
  42. 42.
    Cohen R, Guber A, Siegal A, et al. The prognostic application of cytokeratin typing of nonsmall cell lung carcinoma. Cancer 79:468–473, 1997.PubMedCrossRefGoogle Scholar
  43. 43.
    Bhatavdekar JM, Patel DD, Chikhlikar PR, et al. Molecular markers are predictors of recurrence and survival in patients with Dukes B and Dukes C colorectal adenocarcinoma. Dis Colon Rectum 44:523–533, 2001.PubMedCrossRefGoogle Scholar
  44. 44.
    Jones C, Nonni AV, Fulford L, et al. CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. Br J Cancer 85:422–427, 2001.PubMedCrossRefGoogle Scholar
  45. 45.
    Albores-Saavedra J, Krueger JE. C-cell hyperplasia and medullary thyroid microcarcinoma. Endocr Pathol 12:365–377, 2001.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2002

Authors and Affiliations

  • C. David Bell
    • 1
    • 2
  • Sergio Vidal
    • 3
  • Kalman Kovacs
    • 1
    • 2
  • Eva Horvath
    • 1
    • 2
  • Fabio Rotondo
    • 1
  1. 1.Division of Pathology, Department of Laboratory Medicine and PathobiologySt. Michael’s HospitalTorontoCanada
  2. 2.Faculty of MedicineUniversity of TorontoTorontoCanada
  3. 3.Department of AnatomyUniversity of Santiago de CompostelaLugoSpain

Personalised recommendations